Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
57.89 USD | -6.78% | -11.01% | -30.66% |
May. 09 | Oppenheimer Adjusts Cytokinetics Price Target to $106 From $107, Maintains Outperform Rating | MT |
May. 08 | Cytokinetics Q1 Net Loss Narrows, Revenue Declines | MT |
Financials (USD)
Sales 2024 * | 9.69M | Sales 2025 * | 75.22M | Capitalization | 6.07B |
---|---|---|---|---|---|
Net income 2024 * | -490M | Net income 2025 * | -466M | EV / Sales 2024 * | 623 x |
Net cash position 2024 * | 33.92M | Net cash position 2025 * | 417M | EV / Sales 2025 * | 75.2 x |
P/E ratio 2024 * |
-12.2
x | P/E ratio 2025 * |
-13.8
x | Employees | 423 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.15% |
Latest transcript on Cytokinetics, Incorporated
1 day | -6.78% | ||
1 week | -11.01% | ||
Current month | -5.59% | ||
1 month | -19.10% | ||
3 months | -24.85% | ||
6 months | +80.85% | ||
Current year | -30.66% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Blum
CEO | Chief Executive Officer | 60 | 98-06-30 |
Kari Loeser
CMP | Compliance Officer | - | 21-10-31 |
Stuart Kupfer
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy Wysenski
BRD | Director/Board Member | 66 | 20-11-19 |
Edward Kaye
BRD | Director/Board Member | 74 | 16-05-19 |
Santo Costa
BRD | Director/Board Member | 78 | 10-09-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.44% | 0 M€ | 0.00% | - | |
0.39% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 57.89 | -6.78% | 3,552,193 |
24-05-10 | 62.1 | -3.00% | 1,343,714 |
24-05-09 | 64.02 | -1.92% | 2,404,751 |
24-05-08 | 65.27 | -0.02% | 1,174,612 |
24-05-07 | 65.28 | +0.35% | 849,388 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.66% | 6.07B | |
+5.66% | 111B | |
+11.23% | 105B | |
-2.18% | 21.93B | |
-12.15% | 22.34B | |
-6.22% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- CYTK Stock